ArticleCancers2025

Real-World Evidence of Regorafenib Dose Escalation Versus Fixed Dosing in Refractory Metastatic Colorectal Cancer: Results from the ReTrITA Study.

Carlo Signorelli et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.